Dihexa PNB-0408 is an investigational oligopeptide derived from angiotensin IV that enhances hepatocyte growth factor signaling at the c-Met receptor. Preclinical studies report extremely high neurotrophic potency relative to BDNF, improvements in cognitive function and hippocampal synaptogenesis…
Dihexa, also known by the research code PNB-0408, is an oligopeptide pharmaceutical compound derived from angiotensin IV. Oligopeptides are short chains of amino acids that can be synthesized and modified to interact with specific biological targets. Its chemical formula is C27H44N4O5 and its molar mass is approximately 504.672 grams per mole. These characteristics place it among the small, peptide-based research compounds being studied for neurological applications.
The primary mechanism of action for Dihexa involves hepatocyte growth factor HGF , a signaling protein that normally binds to the receptor c-Met. Dihexa binds directly to HGF with high affinity, rather than binding to the receptor itself. This interaction potentiates HGF's natural activity at c-Met, meaning Dihexa increases the strength or effectiveness of HGF's own signaling. In functional terms, Dihexa acts as an enhancer or positive modulator of HGF signaling, not as a direct activator of the c-Met receptor.
HGF and c-Met participate in a variety of cellular processes, including tissue repair, cell survival, and plasticity in the nervous system. By boosting HGF signaling, Dihexa has the theoretical potential to support pathways relevant to neuron maintenance and memory formation. Understanding this distinction is important because drugs can either mimic a ligand an agonist or amplify the ligand's existing effects, as Dihexa appears to do.
Laboratory research on Dihexa has reported neurotrophic activity that is seven orders of magnitude more potent than brain-derived neurotrophic factor BDNF . Seven orders of magnitude represents a 10 million-fold difference in potency. BDNF is a well-known protein that supports neuron survival, growth, and synaptic function, so this comparison is often used to highlight Dihexa's exceptionally strong activity in experimental systems.
In animal models of Alzheimer's disease, Dihexa demonstrated a capacity to improve cognitive function. Researchers also observed facilitated hippocampal synaptogenesis, which is the formation of new synapses in the hippocampus. Alongside this, the compound was associated with improvements in spatial memory. The hippocampus is a brain region essential for learning and spatial navigation, and its dysfunction is closely tied to the memory deficits seen in Alzheimer's disease. These findings support continued investigation of the compound, though they remain preclinical.
Short-duration safety studies performed during early development uncovered no apparent toxicity. However, HGF/c-Met signaling has known oncogenic potential, because activation of c-Met can promote cell proliferation and survival in certain cancers. This raises a theoretical safety concern for any compound that strengthens c-Met signaling. According to the available research, Dihexa showed a lack of neoplastic induction in the studies that were conducted.
The proposed explanation is that cancer formation requires multiple mutations beyond simple receptor activation. Enhancing HGF signaling alone may not be sufficient to drive tumor development. That said, long-term safety data are still limited, and the oncogenic risk cannot be completely dismissed based on short-term studies alone.
Dihexa was developed by Joseph Harding and his team at Washington State University. M3 Biotechnology was subsequently established to move the compound toward clinical applications. A phosphate pro-drug derivative of Dihexa, called fosgonimeton, is presently undergoing clinical trials for Alzheimer's disease and Parkinson's disease.
A pro-drug is a modified version of a molecule that requires metabolic conversion inside the body to release the active compound. In this case, the phosphate group is likely intended to improve pharmaceutical properties such as solubility, stability, or tissue distribution. The step from a research compound to a clinical candidate is substantial, and ongoing trials will determine whether fosgonimeton demonstrates sufficient safety and efficacy.
At this stage, the evidence for Dihexa comes primarily from laboratory models and early preclinical studies. The potency comparisons, cognitive improvements, and short-term safety findings have not been established in human clinical trials for Dihexa itself. Fosgonimeton, the pro-drug derivative, is in clinical trials, but being in clinical trials does not guarantee eventual approval. Clinical research proceeds through phases designed to assess safety, dosing, and effectiveness, and most investigational candidates do not complete the full process.
Dihexa also remains an unapproved compound. Regulatory agencies have not reviewed it as a medicine for any condition. People who encounter marketing around this peptide should be aware that its human safety profile is incomplete and that claims about cognitive enhancement or disease modification are not supported by clinical evidence.
This resource is for educational purposes only. Dihexa is an investigational peptide, not an approved therapeutic. Nothing in this article should be interpreted as medical advice or as an endorsement of any particular use or supplier.